First Time Loading...

InflaRx NV
NASDAQ:IFRX

Watchlist Manager
InflaRx NV Logo
InflaRx NV
NASDAQ:IFRX
Watchlist
Price: 1.39 USD 2.21%
Updated: Apr 26, 2024

Intrinsic Value

IFRX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. [ Read More ]

The intrinsic value of one IFRX stock under the Base Case scenario is 5.45 USD. Compared to the current market price of 1.39 USD, InflaRx NV is Undervalued by 74%.

Key Points:
IFRX Intrinsic Value
Base Case
5.45 USD
Undervaluation 74%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
InflaRx NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IFRX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
InflaRx NV

Provide an overview of the primary business activities
of InflaRx NV.

What unique competitive advantages
does InflaRx NV hold over its rivals?

What risks and challenges
does InflaRx NV face in the near future?

Summarize the latest earnings call
of InflaRx NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for InflaRx NV.

Provide P/S
for InflaRx NV.

Provide P/E
for InflaRx NV.

Provide P/OCF
for InflaRx NV.

Provide P/FCFE
for InflaRx NV.

Provide P/B
for InflaRx NV.

Provide EV/S
for InflaRx NV.

Provide EV/GP
for InflaRx NV.

Provide EV/EBITDA
for InflaRx NV.

Provide EV/EBIT
for InflaRx NV.

Provide EV/OCF
for InflaRx NV.

Provide EV/FCFF
for InflaRx NV.

Provide EV/IC
for InflaRx NV.

Show me price targets
for InflaRx NV made by professional analysts.

What are the Revenue projections
for InflaRx NV?

How accurate were the past Revenue estimates
for InflaRx NV?

What are the Net Income projections
for InflaRx NV?

How accurate were the past Net Income estimates
for InflaRx NV?

What are the EPS projections
for InflaRx NV?

How accurate were the past EPS estimates
for InflaRx NV?

What are the EBIT projections
for InflaRx NV?

How accurate were the past EBIT estimates
for InflaRx NV?

Compare the revenue forecasts
for InflaRx NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of InflaRx NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of InflaRx NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of InflaRx NV compared to its peers.

Compare the P/E ratios
of InflaRx NV against its peers.

Discuss the investment returns and shareholder value creation
comparing InflaRx NV with its peers.

Analyze the financial leverage
of InflaRx NV compared to its main competitors.

Show all profitability ratios
for InflaRx NV.

Provide ROE
for InflaRx NV.

Provide ROA
for InflaRx NV.

Provide ROIC
for InflaRx NV.

Provide ROCE
for InflaRx NV.

Provide Gross Margin
for InflaRx NV.

Provide Operating Margin
for InflaRx NV.

Provide Net Margin
for InflaRx NV.

Provide FCF Margin
for InflaRx NV.

Show all solvency ratios
for InflaRx NV.

Provide D/E Ratio
for InflaRx NV.

Provide D/A Ratio
for InflaRx NV.

Provide Interest Coverage Ratio
for InflaRx NV.

Provide Altman Z-Score Ratio
for InflaRx NV.

Provide Quick Ratio
for InflaRx NV.

Provide Current Ratio
for InflaRx NV.

Provide Cash Ratio
for InflaRx NV.

What is the historical Revenue growth
over the last 5 years for InflaRx NV?

What is the historical Net Income growth
over the last 5 years for InflaRx NV?

What is the current Free Cash Flow
of InflaRx NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for InflaRx NV.

Financials

Balance Sheet Decomposition
InflaRx NV

Current Assets 109.5m
Cash & Short-Term Investments 90.3m
Receivables 3.8m
Other Current Assets 15.4m
Non-Current Assets 10.7m
Long-Term Investments 9.1m
PP&E 1.4m
Intangibles 68.8k
Other Non-Current Assets 257.3k
Current Liabilities 16.8m
Accounts Payable 12m
Other Current Liabilities 4.9m
Non-Current Liabilities 782.6k
Long-Term Debt 782.6k
Efficiency

Earnings Waterfall
InflaRx NV

Revenue
63.1k EUR
Cost of Revenue
-532.3k EUR
Gross Profit
-469.2k EUR
Operating Expenses
-44.4m EUR
Operating Income
-44.9m EUR
Other Expenses
2.2m EUR
Net Income
-42.7m EUR

Free Cash Flow Analysis
InflaRx NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IFRX Profitability Score
Profitability Due Diligence

InflaRx NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

16/100
Profitability
Score

InflaRx NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

IFRX Solvency Score
Solvency Due Diligence

InflaRx NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
55/100
Solvency
Score

InflaRx NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IFRX Price Targets Summary
InflaRx NV

Wall Street analysts forecast IFRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IFRX is 8.16 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

Lowest
Price Target
5.05 USD
263% Upside
Average
Price Target
8.16 USD
487% Upside
Highest
Price Target
12.6 USD
806% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

IFRX Price
InflaRx NV

1M 1M
-10%
6M 6M
-18%
1Y 1Y
-70%
3Y 3Y
-64%
5Y 5Y
-97%
10Y 10Y
-91%
Annual Price Range
1.39
52w Low
1.25
52w High
5.11
Price Metrics
Average Annual Return -24.8%
Standard Deviation of Annual Returns 54.52%
Max Drawdown -98%
Shares Statistics
Market Capitalization 81.8m USD
Shares Outstanding 58 883 300
Percentage of Shares Shorted 0.71%

IFRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

InflaRx NV Logo
InflaRx NV

Country

Germany

Industry

Biotechnology

Market Cap

81.8m USD

Dividend Yield

0%

Description

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

Contact

THUERINGEN
Jena
Winzerlaer Str. 2
+493641508180.0
https://www.inflarx.de/

IPO

2017-11-16

Employees

59

Officers

Co-Founder, CEO & Executive Director
Dr. Niels C. Riedemann M.D., Ph.D.
Co-Founder, Chief Scientific Officer & Executive Director
Prof. Renfeng Guo M.D.
Chief Financial Officer
Dr. Thomas Taapken Ph.D.
Senior VP and Global Head of Regulatory Affairs & Compliance
Ms. Derval O'Carroll
Chief Medical Officer
Dr. Camilla Chong M.D.
Head of Investor Relations & VP
Mr. Jan Medina CFA
Show More
VP and Head of Legal Affairs & General Counsel
Mr. Christian Schmid
Senior Director & Head of Human Resources
Ms. Nicole Bertsch
VP, Head of Preclinical R&D and QC
Dr. Maria Habel PH.D.
VP & Head of Medical Affairs
Dr. Bruce P. Burnett Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one IFRX stock?

The intrinsic value of one IFRX stock under the Base Case scenario is 5.45 USD.

Is IFRX stock undervalued or overvalued?

Compared to the current market price of 1.39 USD, InflaRx NV is Undervalued by 74%.